H.C. Wainwright analyst Ed Arce raised the firm’s price target on Terns Pharmaceuticals to $11 from $7 and keeps a Neutral rating on the shares post the Q4 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TERN:
- Terns Pharmaceuticals reports Q4 EPS (29c), consensus (43c)
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
- Terns Pharmaceuticals appoints Kuriakose as CMO of Terns oncology
- Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology
- TipRanks ‘Perfect 10’ List: 3 Top-Rated Stocks That Tick All the Right Boxes